Global Generic Nifedipine Controlled-release Tablets 麻豆原创 Research Report 2024

Publication ID:

PB508240202

Publication Date:

August 1, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Nifedipine controlled-release tablets are a type of medication used primarily to treat high blood pressure(hypertension)and certain types of chest pain (angina).Nifedipine belongs to a class of drugs known as calcium channel blockers.These tablets are formulated to release the medication slowly over time,which helps maintain a steady level of the drug in the body and can prolong its therapeutic effect.
The global Generic Nifedipine Controlled-release Tablets market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Generic Nifedipine Controlled-release Tablets is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Generic Nifedipine Controlled-release Tablets is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Generic Nifedipine Controlled-release Tablets include Shanghai Shyndec Pharma, Simcere, Qingdao Baiyang Pharmaceutical, CR DOUBLE-CRANE, Hefei Cube Pharma, Deyao Pharma, Apichope, Nanjing Easeheal Pharma, Beijing Honglin Pharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Generic Nifedipine Controlled-release Tablets, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Nifedipine Controlled-release Tablets.
The Generic Nifedipine Controlled-release Tablets market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Generic Nifedipine Controlled-release Tablets market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Generic Nifedipine Controlled-release Tablets manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Shanghai Shyndec Pharma
Simcere
Qingdao Baiyang Pharmaceutical
CR DOUBLE-CRANE
Hefei Cube Pharma
Deyao Pharma
Apichope
Nanjing Easeheal Pharma
Beijing Honglin Pharma
Segment by Type
30mg per Tablet
60mg per Tablet
Segment by Application
Hypertension
Exertional Angina
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Generic Nifedipine Controlled-release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Generic Nifedipine Controlled-release Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Generic Nifedipine Controlled-release Tablets 麻豆原创 Overview
1.1 Product Definition
1.2 Generic Nifedipine Controlled-release Tablets by Type
1.2.1 Global Generic Nifedipine Controlled-release Tablets 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 30mg per Tablet
1.2.3 60mg per Tablet
1.3 Generic Nifedipine Controlled-release Tablets by Application
1.3.1 Global Generic Nifedipine Controlled-release Tablets 麻豆原创 Value by Application (2024-2030)
1.3.2 Hypertension
1.3.3 Exertional Angina
1.3.4 Other
1.4 Global Generic Nifedipine Controlled-release Tablets 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Generic Nifedipine Controlled-release Tablets Revenue 2019-2030
1.4.2 Global Generic Nifedipine Controlled-release Tablets Sales 2019-2030
1.4.3 Global Generic Nifedipine Controlled-release Tablets 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Generic Nifedipine Controlled-release Tablets 麻豆原创 Competition by Manufacturers
2.1 Global Generic Nifedipine Controlled-release Tablets Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Generic Nifedipine Controlled-release Tablets Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Generic Nifedipine Controlled-release Tablets Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Generic Nifedipine Controlled-release Tablets, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Generic Nifedipine Controlled-release Tablets, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Generic Nifedipine Controlled-release Tablets, Product Type & Application
2.7 Global Key Manufacturers of Generic Nifedipine Controlled-release Tablets, Date of Enter into This Industry
2.8 Global Generic Nifedipine Controlled-release Tablets 麻豆原创 Competitive Situation and Trends
2.8.1 Global Generic Nifedipine Controlled-release Tablets 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Generic Nifedipine Controlled-release Tablets Players 麻豆原创 Share by Revenue
2.8.3 Global Generic Nifedipine Controlled-release Tablets 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Generic Nifedipine Controlled-release Tablets 麻豆原创 Scenario by Region
3.1 Global Generic Nifedipine Controlled-release Tablets 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Generic Nifedipine Controlled-release Tablets Sales by Region: 2019-2030
3.2.1 Global Generic Nifedipine Controlled-release Tablets Sales by Region: 2019-2024
3.2.2 Global Generic Nifedipine Controlled-release Tablets Sales by Region: 2025-2030
3.3 Global Generic Nifedipine Controlled-release Tablets Revenue by Region: 2019-2030
3.3.1 Global Generic Nifedipine Controlled-release Tablets Revenue by Region: 2019-2024
3.3.2 Global Generic Nifedipine Controlled-release Tablets Revenue by Region: 2025-2030
3.4 North America Generic Nifedipine Controlled-release Tablets 麻豆原创 Facts & Figures by Country
3.4.1 North America Generic Nifedipine Controlled-release Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Generic Nifedipine Controlled-release Tablets Sales by Country (2019-2030)
3.4.3 North America Generic Nifedipine Controlled-release Tablets Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Generic Nifedipine Controlled-release Tablets 麻豆原创 Facts & Figures by Country
3.5.1 Europe Generic Nifedipine Controlled-release Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Generic Nifedipine Controlled-release Tablets Sales by Country (2019-2030)
3.5.3 Europe Generic Nifedipine Controlled-release Tablets Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Generic Nifedipine Controlled-release Tablets 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Generic Nifedipine Controlled-release Tablets 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Generic Nifedipine Controlled-release Tablets Sales by Region (2019-2030)
3.6.3 Asia Pacific Generic Nifedipine Controlled-release Tablets Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Generic Nifedipine Controlled-release Tablets 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Generic Nifedipine Controlled-release Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Generic Nifedipine Controlled-release Tablets Sales by Country (2019-2030)
3.7.3 Latin America Generic Nifedipine Controlled-release Tablets Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Generic Nifedipine Controlled-release Tablets 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Generic Nifedipine Controlled-release Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Generic Nifedipine Controlled-release Tablets Sales by Country (2019-2030)
3.8.3 Middle East and Africa Generic Nifedipine Controlled-release Tablets Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Generic Nifedipine Controlled-release Tablets Sales by Type (2019-2030)
4.1.1 Global Generic Nifedipine Controlled-release Tablets Sales by Type (2019-2024)
4.1.2 Global Generic Nifedipine Controlled-release Tablets Sales by Type (2025-2030)
4.1.3 Global Generic Nifedipine Controlled-release Tablets Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Generic Nifedipine Controlled-release Tablets Revenue by Type (2019-2030)
4.2.1 Global Generic Nifedipine Controlled-release Tablets Revenue by Type (2019-2024)
4.2.2 Global Generic Nifedipine Controlled-release Tablets Revenue by Type (2025-2030)
4.2.3 Global Generic Nifedipine Controlled-release Tablets Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Generic Nifedipine Controlled-release Tablets Price by Type (2019-2030)
5 Segment by Application
5.1 Global Generic Nifedipine Controlled-release Tablets Sales by Application (2019-2030)
5.1.1 Global Generic Nifedipine Controlled-release Tablets Sales by Application (2019-2024)
5.1.2 Global Generic Nifedipine Controlled-release Tablets Sales by Application (2025-2030)
5.1.3 Global Generic Nifedipine Controlled-release Tablets Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Generic Nifedipine Controlled-release Tablets Revenue by Application (2019-2030)
5.2.1 Global Generic Nifedipine Controlled-release Tablets Revenue by Application (2019-2024)
5.2.2 Global Generic Nifedipine Controlled-release Tablets Revenue by Application (2025-2030)
5.2.3 Global Generic Nifedipine Controlled-release Tablets Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Generic Nifedipine Controlled-release Tablets Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Shanghai Shyndec Pharma
6.1.1 Shanghai Shyndec Pharma Company Information
6.1.2 Shanghai Shyndec Pharma Description and Business Overview
6.1.3 Shanghai Shyndec Pharma Generic Nifedipine Controlled-release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Shanghai Shyndec Pharma Generic Nifedipine Controlled-release Tablets Product Portfolio
6.1.5 Shanghai Shyndec Pharma Recent Developments/Updates
6.2 Simcere
6.2.1 Simcere Company Information
6.2.2 Simcere Description and Business Overview
6.2.3 Simcere Generic Nifedipine Controlled-release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Simcere Generic Nifedipine Controlled-release Tablets Product Portfolio
6.2.5 Simcere Recent Developments/Updates
6.3 Qingdao Baiyang Pharmaceutical
6.3.1 Qingdao Baiyang Pharmaceutical Company Information
6.3.2 Qingdao Baiyang Pharmaceutical Description and Business Overview
6.3.3 Qingdao Baiyang Pharmaceutical Generic Nifedipine Controlled-release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Qingdao Baiyang Pharmaceutical Generic Nifedipine Controlled-release Tablets Product Portfolio
6.3.5 Qingdao Baiyang Pharmaceutical Recent Developments/Updates
6.4 CR DOUBLE-CRANE
6.4.1 CR DOUBLE-CRANE Company Information
6.4.2 CR DOUBLE-CRANE Description and Business Overview
6.4.3 CR DOUBLE-CRANE Generic Nifedipine Controlled-release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.4.4 CR DOUBLE-CRANE Generic Nifedipine Controlled-release Tablets Product Portfolio
6.4.5 CR DOUBLE-CRANE Recent Developments/Updates
6.5 Hefei Cube Pharma
6.5.1 Hefei Cube Pharma Company Information
6.5.2 Hefei Cube Pharma Description and Business Overview
6.5.3 Hefei Cube Pharma Generic Nifedipine Controlled-release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Hefei Cube Pharma Generic Nifedipine Controlled-release Tablets Product Portfolio
6.5.5 Hefei Cube Pharma Recent Developments/Updates
6.6 Deyao Pharma
6.6.1 Deyao Pharma Company Information
6.6.2 Deyao Pharma Description and Business Overview
6.6.3 Deyao Pharma Generic Nifedipine Controlled-release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Deyao Pharma Generic Nifedipine Controlled-release Tablets Product Portfolio
6.6.5 Deyao Pharma Recent Developments/Updates
6.7 Apichope
6.7.1 Apichope Company Information
6.7.2 Apichope Description and Business Overview
6.7.3 Apichope Generic Nifedipine Controlled-release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Apichope Generic Nifedipine Controlled-release Tablets Product Portfolio
6.7.5 Apichope Recent Developments/Updates
6.8 Nanjing Easeheal Pharma
6.8.1 Nanjing Easeheal Pharma Company Information
6.8.2 Nanjing Easeheal Pharma Description and Business Overview
6.8.3 Nanjing Easeheal Pharma Generic Nifedipine Controlled-release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Nanjing Easeheal Pharma Generic Nifedipine Controlled-release Tablets Product Portfolio
6.8.5 Nanjing Easeheal Pharma Recent Developments/Updates
6.9 Beijing Honglin Pharma
6.9.1 Beijing Honglin Pharma Company Information
6.9.2 Beijing Honglin Pharma Description and Business Overview
6.9.3 Beijing Honglin Pharma Generic Nifedipine Controlled-release Tablets Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Beijing Honglin Pharma Generic Nifedipine Controlled-release Tablets Product Portfolio
6.9.5 Beijing Honglin Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Generic Nifedipine Controlled-release Tablets Industry Chain Analysis
7.2 Generic Nifedipine Controlled-release Tablets Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Generic Nifedipine Controlled-release Tablets Production Mode & Process
7.4 Generic Nifedipine Controlled-release Tablets Sales and 麻豆原创ing
7.4.1 Generic Nifedipine Controlled-release Tablets Sales Channels
7.4.2 Generic Nifedipine Controlled-release Tablets Distributors
7.5 Generic Nifedipine Controlled-release Tablets Customers
8 Generic Nifedipine Controlled-release Tablets 麻豆原创 Dynamics
8.1 Generic Nifedipine Controlled-release Tablets Industry Trends
8.2 Generic Nifedipine Controlled-release Tablets 麻豆原创 Drivers
8.3 Generic Nifedipine Controlled-release Tablets 麻豆原创 Challenges
8.4 Generic Nifedipine Controlled-release Tablets 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Shanghai Shyndec Pharma
Simcere
Qingdao Baiyang Pharmaceutical
CR DOUBLE-CRANE
Hefei Cube Pharma
Deyao Pharma
Apichope
Nanjing Easeheal Pharma
Beijing Honglin Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.